Awakn Life Sciences Announces Credit Facility Dec 18, 2024 08:30AM
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc Dec 16, 2024 08:30AM
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program Dec 10, 2024 05:30PM
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites Oct 22, 2024 07:30AM
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program Oct 15, 2024 07:30AM


Oct 4, 2024 07:30AM Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Sep 18, 2024 07:30AM Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Aug 28, 2024 07:30AM Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Aug 9, 2024 07:30AM Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Jul 31, 2024 07:30AM Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Jul 22, 2024 05:00PM Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Jul 18, 2024 07:30AM Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC